- Home
- NSTS vs ATNM Comparison
NSTS vs ATNM Comparison
Compare NSTS & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSTS | ATNM |
|---|---|---|
| Founded | 1921 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.7M | 50.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NSTS | ATNM |
|---|---|---|
| Price | $11.66 | $1.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 5.6K | ★ 204.3K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,762,000.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $42,943.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 57.78 | 11.11 |
| 52 Week Low | $10.72 | $1.03 |
| 52 Week High | $13.32 | $2.41 |
Technical Indicators
Market Signals| Indicator | NSTS | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 66.32 | 52.42 |
| Support Level | $11.14 | $1.33 |
| Resistance Level | $11.75 | $1.54 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 88.00 | 51.43 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.